Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 2.44% is 76% below its 5-year average of 10.28%, near the low end of its 5-year range (0.34%–14.62%).
82.55% below its 12-month average of 13.98%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
2.44%
RETURN ON ASSETS (ROA) AVG TTM
13.98%
RETURN ON ASSETS (ROA) AVG 3Y
10.40%
RETURN ON ASSETS (ROA) AVG 5Y
10.28%
RETURN ON ASSETS (ROA) AVG 10Y
8.37%
RETURN ON ASSETS (ROA) AVG 15Y
7.56%
RETURN ON ASSETS (ROA) AVG 20Y
8.38%
CURRENT VS TTM AVG
-82.55%
CURRENT VS 3Y AVG
-76.54%
CURRENT VS 5Y AVG
-76.26%
CURRENT VS 10Y AVG
-70.85%
CURRENT VS 15Y AVG
-67.72%
CURRENT VS 20Y AVG
-70.89%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-52.53%
vs the sector median at left
Merck & Co., Inc.
Market Cap
$357.41B
Return on Assets (ROA)
2.44%
TTM Avg
13.98%
3Y Avg
10.40%
5Y Avg
10.28%
Market Cap
$352.61B
Return on Assets (ROA)
4.56%
TTM Avg
4.36%
3Y Avg
6.27%
5Y Avg
6.84%
Market Cap
$339.06B
Return on Assets (ROA)
12.78%
TTM Avg
10.46%
3Y Avg
11.93%
5Y Avg
13.23%
Market Cap
$450.50B
Return on Assets (ROA)
4.67%
TTM Avg
3.16%
3Y Avg
4.61%
5Y Avg
4.90%
Market Cap
$247.58B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$224.15B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$195.43B
Return on Assets (ROA)
19.90%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$179.79B
Return on Assets (ROA)
-6.56%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $357.41B | 2.44% | 13.98% | 10.40% | 10.28% |
| UnitedHealth Group Incorporated (UNH)vs › | $352.61B | 4.56% | 4.36% | 6.27% | 6.84% |
| Roche Holding AG (RHHBY)vs › | $339.06B | 12.78% | 10.46% | 11.93% | 13.23% |
| AbbVie Inc. (ABBV)vs › | $450.50B | 4.67% | 3.16% | 4.61% | 4.90% |
| AstraZeneca PLC (AZN)vs › | $247.58B | 9.03% | 7.88% | 6.26% | 4.99% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.15B | 6.17% | 6.31% | 6.46% | 7.20% |
| Amgen Inc. (AMGN)vs › | $206.42B | 9.14% | 6.48% | 7.48% | 8.52% |
| Novo Nordisk A/S (NVO)vs › | $195.43B | 19.90% | 20.27% | 22.54% | 48.60% |
| Gilead Sciences, Inc. (GILD)vs › | $179.79B | -6.56% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT)vs › | $178.87B | 4.97% | 11.99% | 10.28% | 9.45% |
ROA
2.4%
ROE
7.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 13.34% |
| 2024-12-31 | 14.62% |
| 2023-12-31 | 0.34% |
| 2022-12-31 | 13.30% |
| 2021-12-31 | 12.35% |
| 2020-12-31 | 7.72% |
| 2019-12-31 | 11.66% |
| 2018-12-31 | 7.53% |
| 2017-12-31 | 2.72% |
| 2016-12-31 | 4.11% |
| 2015-12-31 | 4.37% |
| 2014-12-31 | 12.14% |
| 2013-12-31 | 4.17% |
| 2012-12-31 | 5.81% |
| 2011-12-31 | 5.97% |
| 2010-12-31 | 0.81% |
| 2009-12-31 | 11.48% |
| 2008-12-31 | 16.54% |
| 2007-12-31 | 6.77% |
| 2006-12-31 | 9.95% |
| 2005-12-31 | 10.33% |
| 2004-12-31 | 13.69% |
| 2003-12-31 | 16.83% |
| 2002-12-31 | 15.03% |
| 2001-12-31 | 16.54% |
| 2000-12-31 | 17.09% |
| 1999-12-31 | 16.53% |
| 1998-12-31 | 16.48% |
| 1997-12-31 | 17.93% |
| 1996-12-31 | 15.98% |
